Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene therapy and, recently, to the market approval of an AAV-based drug in Europe. With clinical development, however, it became obvious that the host immune system represents an important obstacle to successful gene transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxic T cell responses directed against the AAV capsid encountered on human studies. While over the past several years the field has acquired a tremendous amount of information on the interactions of AAV vectors with the immune system, a lot of questions are still unanswered. Novel concepts are emerging, such as the relationship between the total capsid dose and the T cell-mediated clearance of transduced cells, the potential role of innate immunity in vector immunogenicity highlighted in preclinical studies, and the cross talk between regulatory and effector T cells in the determination of the outcome of gene transfer. There is still a lot to learn about immune responses in AAV gene transfer, for example, it is not well understood what are the determinants of the kinetics of activation of T cells in response to vector administration, why not all subjects develop detrimental T cell responses following gene transfer, and whether the intervention strategies currently in use to block T cell-mediated clearance of transduced cells will be safe and effective for all gene therapy indications. Results from novel preclinical models and clinical studies will help to address these points and to reach the important goal of developing safe and effective gene therapy protocols to treat human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 10×
“In particular, in the AAV8-FIX study vector administration resulted in the activation of capsid-specific CD8 T cells, with an increase in liver enzymes that required intervention with corticosteroids detected in four out of six subjects (9, 84) from the highdose cohort, who received 2× 1012 vg/kg of vector, ~8–9 weeks…”
BackgroundResultInfluentialSelf-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Research works printed but not linked: 54
- Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158 · DOI · Paper page
- Cideciyan, 2008, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics, Proc Natl Acad Sci U S A, 105, 15112, 10.1073/pnas.0807027105 · DOI · Paper page
- Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI · Paper page
- Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat Rev Genet, 12, 301, 10.1038/nrg2985 · DOI · Paper page
- Buning, 2013, Gene therapy enters the pharma market: the short story of a long journey, EMBO Mol Med, 5, 1, 10.1002/emmm.201202291 · DOI · Paper page
- Li, 2007, Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo, J Virol, 81, 7540, 10.1128/JVI.00529-07 · DOI · Paper page
- Li, 2007, Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes, Mol Ther, 15, 792, 10.1038/mt.sj.6300090 · doi:10.1038/mt.sj.6300090
- Martino, 2013, Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells, Blood, 121, 2224, 10.1182/blood-2012-10-460733 · DOI · Paper page
- Muzyczka, 2001, Parvoviridae: The Viruses and Their Replication
- Sonntag, 2010, A viral assembly factor promotes AAV2 capsid formation in the nucleolus, Proc Natl Acad Sci U S A, 107, 10220, 10.1073/pnas.1001673107 · DOI · Paper page
- Zhou, 1998, In vitro packaging of adeno-associated virus DNA, J Virol, 72, 3241, 10.1128/JVI.72.4.3241-3247.1998 · DOI · Paper page
- Atchison, 1965, Adenovirus-associated defective virus particles, Science, 149, 754, 10.1126/science.149.3685.754 · DOI · Paper page
- Arechavaleta-Velasco, 2008, Adverse reproductive outcomes in urban women with adeno-associated virus-2 infections in early pregnancy, Hum Reprod, 23, 29, 10.1093/humrep/dem360 · DOI
- Rogers, 2011, Innate immune responses to AAV Vectors, Front Microbiol, 2, 194, 10.3389/fmicb.2011.00194 · DOI · Paper page
- Zwart, 2009, An experimental test of the independent action hypothesis in virus-insect pathosystems, Proc Biol Sci, 276, 2233, 10.1098/rspb.2009.0064 · DOI
- Martino, 2011, The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver, Blood, 117, 6459, 10.1182/blood-2010-10-314518 · DOI · Paper page
- Buchlis, 2012, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer, Blood, 119, 3038, 10.1182/blood-2011-09-382317 · DOI · Paper page
- Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
- Wang, 2005, Major role of local immune responses in antibody formation to factor IX in AAV gene transfer, Gene Ther, 12, 1453, 10.1038/sj.gt.3302539 · DOI
- Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
- Haurigot, 2010, Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs, Mol Ther, 18, 1318, 10.1038/mt.2010.73 · DOI · Paper page
- Toromanoff, 2010, Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle, Mol Ther, 18, 151, 10.1038/mt.2009.251 · DOI · Paper page
- Sun, 2007, Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance, Am J Hum Genet, 81, 1042, 10.1086/522236 · DOI
- Annoni, 2013, Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice, EMBO Mol Med, 5, 1684, 10.1002/emmm.201302857 · DOI · Paper page
- Cao, 2007, Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer, Blood, 110, 1132, 10.1182/blood-2007-02-073304 · DOI · Paper page
- Martino, 2009, Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity, PLoS One, 4, e6376, 10.1371/journal.pone.0006376 · DOI · Paper page
- Follenzi, 2004, Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice, Blood, 103, 3700, 10.1182/blood-2003-09-3217 · DOI · Paper page
- Breous, 2011, Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver, Gastroenterology, 141, 348, 10.1053/j.gastro.2011.04.002 · DOI · Paper page
- Matzinger, 2002, The danger model: a renewed sense of self, Science, 296, 301, 10.1126/science.1071059 · DOI · Paper page
- He, 2013, Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical, Hum Gene Ther, 24, 545, 10.1089/hum.2013.065 · DOI · Paper page
- Oliveira, 2013, Importance of TAP-independent processing pathways, Mol Immunol, 55, 113, 10.1016/j.molimm.2012.10.005 · DOI
- Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 19, 288, 10.1038/gt.2011.90 · DOI · Paper page
- Erles, 1999, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), J Med Virol, 59, 406, 10.1002/(SICI)1096-9071(199911)59:3406::AID-JMV223.0.CO;2-N · doi:10.1002/(sici)1096-9071(199911)59:3406::aid-jmv223.0.co;2-n
- Hui, 2012, Characterization of AAV T cell epitopes presented by splenocytes from normal human donors, Mol Ther ASGCT Annu Meet Abstr, 20, S557
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci U S A, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Basner-Tschakarjan, 2013, Cellular immune responses to vector in a gene therapy trial for hemophilia b using an AAV8 self-complementary factor IX vector, Blood Am Soc Hematol Annu Meet, 122, 21
- Flotte, 2005, Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy, Hum Gene Ther, 16, 921, 10.1089/hum.2005.16.921 · DOI · Paper page
- Herson, 2012, A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 135, 483, 10.1093/brain/awr342 · DOI · Paper page
- Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol, 66, 290, 10.1002/ana.21732 · DOI · Paper page
- Ozeri, 2012, Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells, J Immunol, 189, 146, 10.4049/jimmunol.1101340 · DOI
- Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
- Finn, 2012, The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy, Blood, 120, 4521, 10.1182/blood-2012-06-440123 · DOI · Paper page
- Siner, 2013, Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype, Blood, 121, 4396, 10.1182/blood-2012-10-464164 · DOI · Paper page
- Nair, 2014, Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy, Blood, 123, 3195, 10.1182/blood-2013-10-534032 · DOI · Paper page
- Ward, 2011, Codon optimization of human factor VIII cDNAs leads to high-level expression, Blood, 117, 798, 10.1182/blood-2010-05-282707 · DOI · Paper page
- Alé, 2014, Neurotoxicity induced by antineoplastic proteasome inhibitors, Neurotoxicology, 10.1016/j.neuro.2014.02.001 · DOI
- Wang, 2012, Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies, Mol Ther, 20, 1501, 10.1038/mt.2012.111 · DOI · Paper page
- Finn, 2010, Rabbit anti-thymocyte globulin (rATG) administrated concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques, Blood, 116, 3765, 10.1182/blood.V116.21.3765.3765 · DOI
- De Groot, 2008, Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopesâ€, Blood, 112, 3303, 10.1182/blood-2008-02-138073 · DOI · Paper page
- Hui, 2013, Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes, Mol Ther, 21, 1727, 10.1038/mt.2013.166 · DOI · Paper page
- Cousens, 2013, Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes, J Diabetes Res, 2013, 621693, 10.1155/2013/621693 · DOI
- van der Marel, 2012, Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis, World J Gastroenterol, 18, 4288, 10.3748/wjg.v18.i32.4288 · DOI
- Britten, 2011, Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunol Immunother, 60, 15, 10.1007/s00262-010-0940-z · DOI
- Britten, 2013, Immunological monitoring to rationally guide AAV gene therapy, Front Immunol, 4, 273, 10.3389/fimmu.2013.00273 · DOI
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“Additionally, unlike previous viral delivery strategies, rAAV does not contain any viral genes, therefore there will be no active viral gene expression to amplify the immune response [66].”
BackgroundDevelopment of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371
“adeno-associated virus (rAAV), due to their high infection efficiency and very low immune response (5).”
BackgroundUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Self-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Chemical modification of the adeno-associated virus capsid to improve gene delivery
Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., et al. (2020) · Chemical Science · doi:10.1039/c9sc04189c · Cited by 92
Metadata
- Authors
- Basner-Tschakarjan, E., & Mingozzi, F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-07-23
- Volume
- 5
- Pages
- 350-350
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2053755635
- Cited by
- 95
- References
- 68
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. https://app.cochat.ai/papers/10.3389/fimmu.2014.00350
- The paper
- Basner-Tschakarjan, E., & Mingozzi, F. (2014). Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2014.00350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.